- Home
- SDHC vs ESPR Comparison
SDHC vs ESPR Comparison
Compare SDHC & ESPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SDHC
- ESPR
- Stock Information
- Founded
- SDHC 2008
- ESPR 2008
- Country
- SDHC United States
- ESPR United States
- Employees
- SDHC N/A
- ESPR N/A
- Industry
- SDHC
- ESPR Biotechnology: Pharmaceutical Preparations
- Sector
- SDHC
- ESPR Health Care
- Exchange
- SDHC Nasdaq
- ESPR Nasdaq
- Market Cap
- SDHC 794.4M
- ESPR 660.1M
- IPO Year
- SDHC 2024
- ESPR 2013
- Fundamental
- Price
- SDHC $19.28
- ESPR $4.00
- Analyst Decision
- SDHC Hold
- ESPR Buy
- Analyst Count
- SDHC 5
- ESPR 7
- Target Price
- SDHC $16.70
- ESPR $6.86
- AVG Volume (30 Days)
- SDHC 86.3K
- ESPR 7.4M
- Earning Date
- SDHC 11-05-2025
- ESPR 11-06-2025
- Dividend Yield
- SDHC N/A
- ESPR N/A
- EPS Growth
- SDHC N/A
- ESPR N/A
- EPS
- SDHC N/A
- ESPR N/A
- Revenue
- SDHC $998,173,000.00
- ESPR $303,802,000.00
- Revenue This Year
- SDHC $1.27
- ESPR $18.83
- Revenue Next Year
- SDHC $8.41
- ESPR N/A
- P/E Ratio
- SDHC N/A
- ESPR N/A
- Revenue Growth
- SDHC 10.26
- ESPR 2.83
- 52 Week Low
- SDHC $15.00
- ESPR $0.69
- 52 Week High
- SDHC $34.00
- ESPR $4.02
- Technical
- Relative Strength Index (RSI)
- SDHC 64.43
- ESPR 75.37
- Support Level
- SDHC $15.89
- ESPR $2.66
- Resistance Level
- SDHC $17.74
- ESPR $3.26
- Average True Range (ATR)
- SDHC 0.92
- ESPR 0.23
- MACD
- SDHC 0.28
- ESPR 0.11
- Stochastic Oscillator
- SDHC 87.24
- ESPR 98.18
About SDHC Smith Douglas Homes Corp.
Smith Douglas Homes Corp is a company engaged in the design, construction, and sale of single-family homes in some of the highest growth and desirable markets in the Southeastern United States. It is organized into eight geographical divisions which comprise two reportable segments. Its Southeast segment consists of Atlanta, Central Georgia, Charlotte, Greenville, and Raleigh divisions. Its Central segment consists of Alabama, Houston, and Nashville divisions.
About ESPR Esperion Therapeutics Inc.
Esperion Therapeutics Inc is a pharmaceutical company. It specializes in developing and commercializing accessible, oral, once-daily, non-statin medicines for patients struggling with elevated low-density lipoprotein cholesterol. The firm has the business of researching, developing and commercializing therapies for the treatment of patients with the elevated low-density lipoprotein cholesterol operating segment. Its products include NEXLETOL, NEXLIZET, NILEMDO and NUSTENDI. The company manages its business in one operating segment, which is the business of researching, developing and commercializing therapies for the treatment of patients with elevated LDL-C.